Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/42990
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Deiana, Valeria | en_US |
dc.contributor.author | Gómez-Cañas, María | en_US |
dc.contributor.author | Pazos, M. Ruth | en_US |
dc.contributor.author | Fernández-Ruiz, Javier | en_US |
dc.contributor.author | Asproni, Battistina | en_US |
dc.contributor.author | Cichero, Elena | en_US |
dc.contributor.author | Fossa, Paola | en_US |
dc.contributor.author | Muñoz, Eduardo | en_US |
dc.contributor.author | Deligia, Francesco | en_US |
dc.contributor.author | Murineddu, Gabriele | en_US |
dc.contributor.author | García-Arencibia, Moisés | en_US |
dc.contributor.author | Pinna, Gerard A. | en_US |
dc.date.accessioned | 2018-11-21T11:59:19Z | - |
dc.date.available | 2018-11-21T11:59:19Z | - |
dc.date.issued | 2016 | en_US |
dc.identifier.issn | 0223-5234 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/42990 | - |
dc.description.abstract | Previous studies have investigated the relevance and structure-activity relationships (SARs) of pyrazole derivatives in relation with cannabinoid receptors, and the series of tricyclic 1,4-dihydroindeno[1,2-c]pyrazoles emerged as potent CB2 receptor ligands. In the present study, novel 1,4-dihydroindeno[1,2-c]pyrazole and 1H-benzo[g]indazole carboxamides containing a cyclopropyl or a cyclohexyl substituent were designed and synthesized to evaluate the influence of these structural modifications towards CB1 and CB2 receptor affinities. Among these derivatives, compound 15 (6-cyclopropyl-1-(2,4-dichlorophenyl)-N-(adamantan-1-yl)-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide) showed the highest CB2 receptor affinity (Ki = 4 nM) and remarkable selectivity (KiCB1/KiCB2 = 2232), whereas a similar affinity, within the nM range, was seen for the fenchyl derivative (compound 10: Ki = 6 nM), for the bornyl analogue (compound 14: Ki = 38 nM) and, to a lesser extent, for the aminopiperidine derivative (compound 6: Ki = 69 nM). Compounds 10 and 14 were also highly selective for the CB2 receptor (KiCB1/KiCB2 > 1000), whereas compound 6 was relatively selective (KiCB1/KiCB2 = 27). The four compounds were also subjected to GTPγS binding analysis showing antagonist/inverse agonist properties (IC50 for compound 14 = 27 nM, for 15 = 51 nM, for 10 = 80 nM and for 6 = 294 nM), and this activity was confirmed for the three more active compounds in a CB2 receptor-specific in vitro bioassay consisting in the quantification of prostaglandin E2 release by LPS-stimulated BV2 cells, in the presence and absence of WIN55,212-2 and/or the investigated compounds. Modelling studies were also conducted with the four compounds, which conformed with the structural requirements stated for the binding of antagonist compounds to the human CB2 receptor. | en_US |
dc.language | eng | en_US |
dc.publisher | 0223-5234 | - |
dc.relation.ispartof | European Journal of Medicinal Chemistry | en_US |
dc.source | European Journal of Medicinal Chemistry [ISSN 0223-5234], v. 112, p. 66-80 | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject.other | CB(2) antagonism | en_US |
dc.subject.other | Cannabinoid receptors | en_US |
dc.subject.other | Molecular modelling | en_US |
dc.subject.other | Synthesis | en_US |
dc.subject.other | Tricyclic pyrazoles | en_US |
dc.title | Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB<inf>2</inf>receptor ligands with antagonist/inverse agonist properties | en_US |
dc.type | info:eu-repo/semantics/Article | es |
dc.type | Article | es |
dc.identifier.doi | 10.1016/j.ejmech.2016.02.005 | |
dc.identifier.scopus | 2-s2.0-84981298101 | - |
dc.identifier.isi | 000372558200007 | |
dc.contributor.authorscopusid | 57194483512 | - |
dc.contributor.authorscopusid | 47761206700 | - |
dc.contributor.authorscopusid | 6701326923 | - |
dc.contributor.authorscopusid | 7006533053 | - |
dc.contributor.authorscopusid | 7801341853 | - |
dc.contributor.authorscopusid | 23970379500 | - |
dc.contributor.authorscopusid | 7004138079 | - |
dc.contributor.authorscopusid | 7202348306 | - |
dc.contributor.authorscopusid | 55241643800 | - |
dc.contributor.authorscopusid | 6603506924 | - |
dc.contributor.authorscopusid | 15821889300 | - |
dc.contributor.authorscopusid | 35546140700 | - |
dc.description.lastpage | 80 | - |
dc.description.firstpage | 66 | - |
dc.relation.volume | 112 | - |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.contributor.daisngid | 3479936 | |
dc.contributor.daisngid | 2056921 | |
dc.contributor.daisngid | 1182976 | |
dc.contributor.daisngid | 180726 | |
dc.contributor.daisngid | 1475866 | |
dc.contributor.daisngid | 749265 | |
dc.contributor.daisngid | 31927177 | |
dc.contributor.daisngid | 76495 | |
dc.contributor.daisngid | 5628976 | |
dc.contributor.daisngid | 974941 | |
dc.contributor.daisngid | 1760567 | |
dc.contributor.daisngid | 267952 | |
dc.contributor.wosstandard | WOS:Deiana, V | |
dc.contributor.wosstandard | WOS:Gomez-Canas, M | |
dc.contributor.wosstandard | WOS:Pazos, MR | |
dc.contributor.wosstandard | WOS:Fernandez-Ruiz, J | |
dc.contributor.wosstandard | WOS:Asproni, B | |
dc.contributor.wosstandard | WOS:Cichero, E | |
dc.contributor.wosstandard | WOS:Fossa, P | |
dc.contributor.wosstandard | WOS:Munoz, E | |
dc.contributor.wosstandard | WOS:Deligia, F | |
dc.contributor.wosstandard | WOS:Murineddu, G | |
dc.contributor.wosstandard | WOS:Garcia-Arencibia, M | |
dc.contributor.wosstandard | WOS:Pinna, GA | |
dc.date.coverdate | Abril 2016 | |
dc.identifier.ulpgc | Sí | es |
dc.description.sjr | 1,272 | |
dc.description.jcr | 4,519 | |
dc.description.sjrq | Q1 | |
dc.description.jcrq | Q1 | |
dc.description.scie | SCIE | |
item.grantfulltext | none | - |
item.fulltext | Sin texto completo | - |
crisitem.author.orcid | 0000-0002-1618-4487 | - |
crisitem.author.fullName | García Arencibia, Moisés | - |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.